Home

Andrew Cheng

CIK 1778307 · President and CEO · last filed 2026-08-13

Andrew Cheng is a President and CEO who has filed 90 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for DMRA, was dated Aug 13, 2026. Across all open-market trades the lifetime net is −$43.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $613.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$613.0K

Companies

4

Total Filings

90

Lifetime Open-Market Net

-$43.39M

Filer Profile

Reported Address
C/O AKERO THERAPEUTICS
601 GATEWAY BLVD #350
SOUTH SAN FRANCISCO, CA 94080
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DMRA Director — $28.10 — $0 1 2026-08-13
VERA Director 17,488 $35.05 $613.0K $0 7 2026-05-26
Akero Therapeutics, Inc. (AKRO) Delisted President and CEO 0 $54.65 $0 -$43.39M 72 2025-12-09
ABUS Director — $5.12 — $0 3 2021-06-07

Recent Filings

90 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-13 DMRA Grant (A) — $0 EDGAR
2026-05-26 VERA Grant (A) — $0 EDGAR
2025-12-09 Akero Therapeutics, Inc. (AKRO) Delisted Disp (D) −436,837 $0 EDGAR
2025-11-21 Akero Therapeutics, Inc. (AKRO) Delisted Gift (G) −74,538 $0 EDGAR
2025-11-13 Akero Therapeutics, Inc. (AKRO) Delisted Gift (G) −14,739 $0 EDGAR
2025-10-14 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$1.02M EDGAR
2025-10-09 Akero Therapeutics, Inc. (AKRO) Delisted Exer (M) +52,212 $32.1K EDGAR
2025-09-12 Akero Therapeutics, Inc. (AKRO) Delisted Mixed −16,855 -$1.25M EDGAR
2025-09-10 Akero Therapeutics, Inc. (AKRO) Delisted Notice (144) −90,000 -$4.02M EDGAR
2025-08-13 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −30,000 -$1.46M EDGAR
Showing 1–10 of 90
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.